The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Meat snacks have become the standout winner in America's GLP-1 consumption shift, surging to a $5.5 billion market as Ozempic and Wegovy users crave protein. Popcorn sales are plummeting amid this protein obsession. Discover the data, expert analysis, and how it's changing snacking habits.
Simon Cowell's latest video before the Britain's Got Talent 2025 finale has fans convinced he's developing 'Ozempic face' due to his noticeably slimmer features and changed eye shape. Social media erupts with comments from 2023 to 2025, even linking him to Ryan Seacrest's look. Despite the buzz, Cowell tells The Sun he's never tried Ozempic.
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
A mother's heartbreaking death after a cheap black market 'skinny jab' has sparked a family's campaign for tougher regulations. Karen McGonigal passed away days after receiving unregulated semaglutide at a beauty salon. Now, her daughters are urging the government to act before more lives are lost.
A Shanghai-based biotech is developing a nasal spray version of semaglutide, the key ingredient in Novo Nordisk's Wegovy, with global clinical trials targeted for completion by 2028. This experimental weight-management spray promises lower costs than tablets and better suitability for long-term use. As Novo's patent nears expiration in China, competition heats up in the booming GLP-1 market.
A subanalysis of the SOUL trial reveals that once-daily oral semaglutide (Rybelsus) lowers the risk of heart failure hospitalization, urgent visits, or CV death by 22% in patients with HF, diabetes, and ASCVD or CKD. Those with preserved ejection fraction (HFpEF) saw even greater protection at 41%. Experts highlight this as a key option for frail patients avoiding injections.
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
A pivotal symposium on 'Nutrition in Clinical Practice: From GLP-1 Era to Cardiac Recovery' drew 150 nutrition professionals to Dhaka's KIB Convention Hall. Chaired by renowned dietician Akhtarun Nahar Alo, the event featured keynote speakers from NICVD and BIRDEM, followed by the launch of Nutricaa Limited's OPTIMA meal replacement. This gathering highlights the growing intersection of GLP-1 therapies and targeted nutrition for cardiac recovery.
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
